Requires substance use disorder treatment centers to provide opioid antidote to certain patients upon discharge.
Take action
Take a stance or write a position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed General Assembly
- Passed Senate
- To Governor
- Became Law
Overview
This bill requires licensed substance use disorder treatment centers in New Jersey to provide naloxone, an opioid antidote, to patients upon discharge. The goal is to prevent overdose deaths by ensuring individuals who have received opioid treatment have access to this life-saving medication. Treatment centers are also required to educate patients about naloxone and how to use it. This legislation aims to increase access to and knowledge of naloxone, ultimately reducing the number of opioid-related fatalities.
Key provisions
- Treatment centers must provide naloxone to patients upon discharge.
- Treatment centers must educate patients on how to administer naloxone.
- The bill applies to licensed substance use disorder treatment centers in New Jersey.
- It mandates the provision of naloxone regardless of the patient’s insurance status.
Who is affected
- Substance use disorder treatment centers
- Patients receiving opioid treatment
- Individuals at risk of opioid overdose
- Healthcare providers in treatment centers
Notable changes
- Creates a requirement for treatment centers to routinely provide naloxone.
- Expands access to naloxone for individuals leaving treatment programs.
Fiscal impact
The bill may have a modest impact on treatment centers' costs associated with purchasing and distributing naloxone.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
1 on record
Primary sponsor
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours